Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

PRESCRIBER		PATIENT:	
Name:		Name:	
Ward:		NHI:	
Midostaurin			
INITIATION Prerequisites (tick boxes where appropriate) Orall Patient has a diagnosis of acute myeloid leukaemia and Orall Condition must be FMS tyrosine kinase 3 (FLT3) mutation positive and Orall Patient must not have received a prior line of intensive chemotherapy for acute myeloid leukaemia and Orall Patient is to receive standard intensive chemotherapy in combination with midostaurin only and Orall Midostaurin to be funded for a maximum of 4 cycles			

I confirm that the above details are correct:

C:	D-1	
Signed.	Date:	
Oigilica.	 Daic.	